Stock Track | Vir Biotechnology Plunges 5.06% Post-Market Following $200 Million Stock Offering Announcement

Stock Track

02/25

Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.

The decline came after the company announced plans for a $200 million public offering of common stock. Equity offerings often lead to stock price pressure due to dilution concerns, as the increase in shares outstanding can reduce existing shareholders' ownership percentages.

This post-market drop followed a strong intraday performance where Vir Biotechnology's stock had soared after reporting better-than-expected fourth-quarter results and announcing a strategic collaboration with Astellas Pharma to develop and commercialize its prostate cancer drug, VIR-5500.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1135785944"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135785944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135785944?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135785944","market":"sg","top_or_hot":-1,"title":"Stock Track | Vir Biotechnology Plunges 5.06% Post-Market Following $200 Million Stock Offering Announcement","media":"Stock Track","content":"<p>Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.</p><p>The decline came after the company announced plans for a $200 million public offering of common stock. Equity offerings often lead to stock price pressure due to dilution concerns, as the increase in shares outstanding can reduce existing shareholders' ownership percentages.</p><p>This post-market drop followed a strong intraday performance where Vir Biotechnology's stock had soared after reporting better-than-expected fourth-quarter results and announcing a strategic collaboration with Astellas Pharma to develop and commercialize its prostate cancer drug, VIR-5500.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vir Biotechnology Plunges 5.06% Post-Market Following $200 Million Stock Offering Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vir Biotechnology Plunges 5.06% Post-Market Following $200 Million Stock Offering Announcement\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-02-25 09:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.</p><p>The decline came after the company announced plans for a $200 million public offering of common stock. Equity offerings often lead to stock price pressure due to dilution concerns, as the increase in shares outstanding can reduce existing shareholders' ownership percentages.</p><p>This post-market drop followed a strong intraday performance where Vir Biotechnology's stock had soared after reporting better-than-expected fourth-quarter results and announcing a strategic collaboration with Astellas Pharma to develop and commercialize its prostate cancer drug, VIR-5500.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":"","article_id":"1135785944","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135785944","pubTimestamp":1771984504,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.The decline came after the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"translate_title":"个股追踪|宣布发行2亿美元股票后Vir Biotechnology盘后暴跌5.06%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":1},"content_text":"Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.The decline came after the company announced plans for a $200 million public offering of common stock. Equity offerings often lead to stock price pressure due to dilution concerns, as the increase in shares outstanding can reduce existing shareholders' ownership percentages.This post-market drop followed a strong intraday performance where Vir Biotechnology's stock had soared after reporting better-than-expected fourth-quarter results and announcing a strategic collaboration with Astellas Pharma to develop and commercialize its prostate cancer drug, VIR-5500.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}